CEO Christophe Beck emphasized "another very strong quarter, once again, very consistent with our guidance," attributing double-digit earnings growth to "relentless focus on execution and delivering ...
MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD’s 2026 business outlook highlights ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results